Pharmaceutical firm Gilead Sciences has come below mounting stress after refusing to promote its breakthrough HIV prevention drug, lenacapavir, on to Médecins Sans Frontières (MSF), regardless of repeated requests.
In an open letter, the group renewed its repeated requests to California-based Gilead to promote the drug, saying the corporate is obstructing lenacapavir’s rollout. MSF stated it had sought to buy a restricted provide of the drug for its international programmes. Nonetheless, Gilead declined, sustaining its place for a number of months.
“Blocking humanitarian organizations from accessing medical breakthroughs places susceptible individuals at risk,” stated Dr. Tom Ellman, director of MSF’s Southern Africa Medical Unit (SAMU).
Sustain with the most recent headlines on WhatsApp | LinkedIn
At present, MSF can solely entry capped provides by way of the World Fund, which Gilead has dedicated to offering for as much as two million individuals over three years in low- and middle-income nations.
Lenacapavir is a long-acting injectable type of pre-exposure prophylaxis (PrEP) administered simply twice a yr. It has been described as a significant development in HIV prevention, notably for susceptible populations in humanitarian settings the place entry to every day treatment is restricted. About 1.3 million individuals worldwide contract HIV yearly. The drug has been in excessive demand since research confirmed that it may supply nearly full safety from an infection with a single dose administered each six months, a follow known as preexposure prophylaxis.
The group has urged Gilead to permit direct purchases, guarantee truthful pricing, and develop provide. It argues that restrictions, in addition to delayed generic entry till 2027, threat leaving many nations with out ample preventative measures.
MSF is in search of an pressing follow-up assembly with Gilead by April 13 to debate the potential for Gilead immediately promoting lenacapavir to MSF, the value at which it will be bought, and when it will be out there to MSF.
